aβ

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Aβ) epitope at the N-terminus, showing potential for early Alzheimer's disease research [1] [2].

Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.

Gantenerumab (R-1450) is a humanized antibody targeting amyloid-β (Aβ), used in studies of Alzheimer's disease.

Bapineuzumab (AAB-001) is a humanised monoclonal antibody targeting amyloid-beta (Aβ), capable of binding to the N-terminal region of both soluble and oligomeric forms of amyloid β, and is used for research into Alzheimer's disease (AD).

Ponezumab (PF-04360365), a humanized anti-amyloid IgG2 monoclonal antibody, effectively lowers Aβ levels in the central nervous system and enhances learning and memory performance in mouse models. It holds potential for Alzheimer's disease research [1].

Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Aβ) for the study of Alzheimer's disease.

Remternetug (LY3372993) is a humanised monoclonal antibody targeting N3pG-Aβ, recognising pyroglutamated Aβ within amyloid plaques, applicable for Alzheimer's disease.

GSK-933776 is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. It comprises a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145.34 kDa. For the isotype control, refer to [HumanIgG1kappa, Isotype Control].

Anti-Amyloid Beta Antibody (DLX212) is a human-derived antibody produced using CHO cells, specifically targeting Amyloid Beta/Aβ. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145.74 kDa. For its isotype control, please refer to Human IgG1 kappa, Isotype Control.

Anti-Amyloid Beta Antibody (CNTO 2125) is a human-derived antibody produced in CHO cells, specifically targeting Amyloid Beta/Aβ. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

MEDI-1814 is a fully human IgG1 antibody targeting the C-terminus of Aβ42. It binds to and eliminates circulating Aβ peptides, thereby preventing their aggregation into toxic oligomers. MEDI-1814 is applicable in Alzheimer's disease research. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Velaprumig is a monoclonal antibody that targets human CD99, CCL25, and anti-human Aβ (Aβ-47F). It regulates immune cell migration, reduces β-amyloid-related pathological processes, and exhibits immunomodulatory and potential anti-Alzheimer's activity.

Dalidnetug is a humanized monoclonal antibody that targets human β-amyloid precursor protein (APP). By specifically binding to APP, Dalidnetug reduces the production of β-amyloid (Aβ), thereby demonstrating activity in clearing β-amyloid. This compound holds potential for research in Alzheimer's disease.